Binder M - Search Results

1

A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C; Study Alliance Leukemia (SAL). Wass M, et al. Among authors: binder m. Leukemia. 2021 Mar;35(3):701-711. doi: 10.1038/s41375-020-0892-z. Epub 2020 Jun 19. Leukemia. 2021. PMID: 32561840 Free PMC article. Clinical Trial.

2

Allogeneic hematopoietic stem cell transplantation: an option for long-term survival for patients with simultaneous appearance of myeloid and lymphatic malignancies.

Weber T, Ocheni S, Binder M, Theurich S, Scheid C, Schmid C, Müller LP, Christopeit M, Bacher U. Weber T, et al. Among authors: binder m. Acta Haematol. 2013;129(3):135-6. doi: 10.1159/000343422. Epub 2012 Nov 29. Acta Haematol. 2013. PMID: 23207834 No abstract available.

3

Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma.

Terziev D, Bauer M, Paschold L, Wickenhauser C, Wienke A, Binder M, Müller LP, Weber T. Terziev D, et al. Among authors: binder m. PLoS One. 2020 Jul 8;15(7):e0235786. doi: 10.1371/journal.pone.0235786. eCollection 2020. PLoS One. 2020. PMID: 32639975 Free PMC article.

4

Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation.

Thiele B, Binder M, Schliffke S, Frenzel C, Dierlamm J, Wass M, Weisel KC, Bokemeyer C, Janjetovic S. Thiele B, et al. Among authors: binder m. Oncol Res Treat. 2021;44(7-8):375-381. doi: 10.1159/000517531. Epub 2021 Jul 21. Oncol Res Treat. 2021. PMID: 34289466 Free PMC article.

5

Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation.

Schaffrath J, Diederichs T, Unverzagt S, Wass M, Gläser U, Weber T, Binder M, Müller-Tidow C, Müller LP. Schaffrath J, et al. Among authors: binder m. Ann Hematol. 2022 Mar;101(3):681-691. doi: 10.1007/s00277-021-04736-0. Epub 2021 Dec 21. Ann Hematol. 2022. PMID: 34932150 Free PMC article.

6

Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas.

Schümann FL, Groß E, Bauer M, Rohde C, Sandmann S, Terziev D, Müller LP, Posern G, Wienke A, Fend F, Hansmann ML, Klapper W, Rosenwald A, Stein H, Dugas M, Müller-Tidow C, Wickenhauser C, Binder M, Weber T. Schümann FL, et al. Among authors: binder m. Biomedicines. 2021 Dec 5;9(12):1842. doi: 10.3390/biomedicines9121842. Biomedicines. 2021. PMID: 34944658 Free PMC article.

7

SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters.

Groß E, Hilger RA, Schümann FL, Bauer M, Bouska A, Rohde C, Willscher E, Lützkendorf J, Müller LP, Edemir B, Mueller T, Herling M, Binder M, Wickenhauser C, Iqbal J, Posern G, Weber T. Groß E, et al. Among authors: binder m. Cancers (Basel). 2023 Jun 3;15(11):3043. doi: 10.3390/cancers15113043. Cancers (Basel). 2023. PMID: 37297005 Free PMC article.

8

Evaluation of BM cytomorphology after allo-SCT in patients with AML.

Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U. Christopeit M, et al. Among authors: binder m. Bone Marrow Transplant. 2012 Dec;47(12):1538-44. doi: 10.1038/bmt.2012.70. Epub 2012 Apr 30. Bone Marrow Transplant. 2012. PMID: 22543745

9

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S. Waizenegger JS, et al. Among authors: binder m. Leukemia. 2015 Mar;29(3):696-704. doi: 10.1038/leu.2014.236. Epub 2014 Aug 8. Leukemia. 2015. PMID: 25102945

10

Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.

Schliffke S, Akyüz N, Ford CT, Mährle T, Thenhausen T, Krohn-Grimberghe A, Knop S, Bokemeyer C, Binder M. Schliffke S, et al. Among authors: binder m. Leukemia. 2016 Nov;30(11):2232-2234. doi: 10.1038/leu.2016.157. Epub 2016 May 25. Leukemia. 2016. PMID: 27220665 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

960 results

Search Page